Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052306 | 0.96 | PDPK1 (0.36) | PDPK1SMPD3ADORA1ADORA2ALOXL2 | |
| SCHEMBL13935681 | 0.89 | PDPK1 (0.38) | PDPK1SMPD3ADORA1ADORA2ALOXL2 | |
| SCHEMBL4268252 | 0.67 | EEF2K (0.37) | PDPK1SMPD3ADORA1ADORA2AALDH1A1 | |
| SCHEMBL497629 | 0.66 | PDPK1 (0.45) | PDPK1SMPD3ADORA1ADORA2ALOXL2 | |
| SCHEMBL102331 | 0.66 | PDPK1 (0.59) | PDPK1SMPD3ADORA1ADORA2ALOXL2 | |
| SCHEMBL11279823 | 0.66 | MAPK14 (0.41) | ALDH1A1MAPTHSP90AA1 | |
| SCHEMBL24373006 | 0.66 | KDM4E (0.33) | ALDH1A1MAPT | |
| SCHEMBL15804313 | 0.66 | PDPK1 (0.34) | PDPK1SMPD3LOXL2CYP2A6 | |
| SCHEMBL678890 | 0.66 | NR1I2 (0.39) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL498174 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | PDPK1 3666/4885SMPD3 2788/4885ADORA1 13/4885 |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | PDPK1 644/4885SMPD3 55/4885ADORA1 234/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | PDPK1 1047/4885SMPD3 3581/4885ADORA1 4620/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | PDPK1 644/4885SMPD3 55/4885ADORA1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.